LOW LDL DOES NOT PROTECT, BUT BIG PHARMA AND HARVARD SAY YES

LOW LDL DOES NOT PROTECT, BUT BIG PHARMA AND HARVARD SAY YES

Amgen, the maker of evolocumab (Repatha) funded the research, paid EVERY author on the paper, led by Harvard researchers, and the findings were published in the prestigious New England Journal of Medicine May 4, 2017. If you take the drug, evolocumab (Repatha), your LDL will go down but you won’t live any longer. IT’S ALL ABOUT INFLAMMATION AND OXIDATION.

MAKE AMERICA HEALTHY™

MAKE AMERICA HEALTHY™

Your health insurance costs are out of control and are the second leading cost for companies, organizations, unions, and governments. To contain costs, employers tried everything without success: less coverage, higher copays, higher deductibles, etc.  America spends the most on health care, ranks last among the top 19 nations, has one of the highest infant mortality rates, obesity rates, and a lower life expectancy. About 80% of all health care dollars are spent on chronic illnesses that are self-induced. And as “excess deaths” rise, health care costs will soar.